Alexion Pharma’s asfotase alfa – also known as Strensiq – has been recommended by the National Institute for Health and Care Excellence (NICE) for use by the NHS in England. It concerns the treatment of paediatric-onset hypophosphatasia (HPP) in infants, children and adults.
NICE’s decision follows an innovative five-year ‘managed access’ agreement initiated in 2017, which enabled patients to have access to treatment while additional data was being generated…
